ROBO1 CAR-NK cell therapy (Asclepius Technology Company Group (Suzhou) Co., Ltd.)

N/A

Report date: 2024/11/22 20:00:28

Base Information

Drug NameROBO1 CAR-NK cell therapy (Asclepius Technology Company Group (Suzhou) Co., Ltd.)
Drug Alias NameROBO1 Specific BiCAR-NK/Tcell therapy (Asclepius Technology Company Group (Suzhou) Co., Ltd.)BiCAR-NK/T cells (Asclepius Technology Company Group (Suzhou) Co., Ltd.)ROBO1 CAR-NK/T cell immunotherapy (Asclepius Technology Company Group (Suzhou) Co., Ltd.)ATCG-427ATCG427 CAR-NK therapy
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Cytokine-induced killer cell > Chimeric antigen receptor CIK cell therapy
Mechanisms of ActionNatural killer cell replacementsRoundabout homolog 1 modulators
TargetsRoundabout homolog 1
Therapy Area/IndicationsSolid tumoursPancreatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaPending
Originator CompaniesAsclepius Technology Company Group
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAsclepius Technology Company Group
Active IndicationsN/A
Inactive IndicationsSolid tumoursPancreatic Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A